Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Gilead’s Sponsored Link For Viread Can’t Prevent Trouble With FDA

This article was originally published in The Pink Sheet Daily

Executive Summary

Agency cites firm for unapproved claim, not including any risk information, and not submitting link to FDA.

You may also be interested in...



FDA Lull In Rx Promotion Citations Continues; Guidances May Be Bigger Priority

Even with recent letters, Office of Prescription Drug Promotion’s slow pace continues from 2014’s record low.

Social Media Marketing: FDA’s Old-Time Approach May Turn Industry Away

Draft guidances say tweets about a product must balance benefit and risk information, and firms cannot be selective in correcting information on third-party sites.

Keywords Not Major Advertising Enforcement Concern, FDA Says

FDA says keywords don’t need OPDP’s formal review, but that doesn’t mean they don’t have an opinion about how they’re used.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

PS077532

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel